Septerna, Inc. (NasdaqGM: SEPN)
Health Care · Pharmaceuticals · US
$37.96
-1.07% today · +59.3% 1Y
Septerna, Inc. (NasdaqGM: SEPN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.79B and employs 123 people.
Over the last twelve months the share price has gained 59.3%, trading between 17.55 and 51.10.
Tweenvest scores Septerna, Inc. across four factors: quality 53/100, value 54/100. Its strongest factor is value.
SEPN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.79B
- Revenue (TTM)
- $98.88M
- P/E
- —
- EPS
- -0.54
- Dividend yield
- —
- Beta (5Y)
- 2.28
- 52-week high
- $51.10
- 52-week low
- $17.55
- Avg volume (3M)
- —
- Shares outstanding
- 46.68M
- Employees
- 123
- Next earnings
- —
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
- ISIN
- US81734D1046
- Founded
- 2019
- Listed since
- Oct 25, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Trevi Therapeutics, Inc.NasdaqGM: TRVI | $1.88B | $13.19 | 0.00% |
| Beijing Aosaikang Pharmaceutical Co., Ltd.SZSE: 002755 | $1.85B | CN¥13.34 | -1.55% |
| Structure Therapeutics Inc.NasdaqGM: GPCR | $1.82B | $24.74 | -3.15% |
| Pfizer LimitedNSEI: PFIZER | $1.80B | Rs3,808.20 | +1.55% |
| Neuren Pharmaceuticals LimitedASX: NEU | $1.79B | AU$20.20 | -0.39% |
| Zhejiang Medicine Co., Ltd.SHSE: 600216 | $1.78B | CN¥12.59 | +1.29% |
| Tsumura & Co.TSE: 4540 | $1.78B | ¥3,772.00 | +1.86% |
| PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725 | $1.77B | CN¥51.01 | -7.84% |
Figures last refreshed Oct 11, 2026.